From bench to bedside to bug: An update of clinically relevant advances in the care of persons with Helicobacter pylori-associated diseases

Canadian Journal of Gastroenterology

Volumn 14, Issue 3, 2000, Pages 188-198

  Chiba, N ^a,b   Thomson, A B R ^c   Sinclair, P ^d  

^a Surrey GI Clinic   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Duodenal ulcer; Functional dyspepsia; Gastric cancer; Helicobacter pylori; Proton pump inhibitor; Urea breath test

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIGEN; BISMUTH; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; NAPROXEN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; UREA;

BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER; STOMACH ULCER;

EID: 0034108734     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/578059     Document Type: Review

References (157)

1. Rothenbacher D, Bode G, Berg G, et al. Major role of mother in transmission of Helicobacter pylori: Results of a population based study among preschool children. Gut 1998;43(Suppl 2):A41. (Abst 05/135)
2. Malaty HM, Kumagai T, Ota H, et al. An 8-year birth cohort study shows adult-to-child transmission of H pylori infection. Gut 1998;43(Suppl 2):A40. (Abst 05/130)
3. García-Arata MI, Parejo R, Camarero C, et al. H pylori typing by ureC gene polymorphism directly from gastric content samples obtained by the string test. Gut 1998;43(Suppl 2):A41 (Abst 05/136)
4. Brenner H, Rothenbacher D, Bode G, Adler, G. The individual and joint contributions of Helicobacter pylon infection and family history to the risk of peptic ulcer. Gut 1998;43(Suppl 2):A43 (Abst 05/143)
5. Gerards C, Arand F, Leodolter A, Bayerdörffer E, Klein U, Malfertheiner P. Prevalence of H pylori infection in family members of H pylori positive patients and its influence on the reinfection rate after successful eradication therapy. Gut 1998;43(Suppl 2):A96 (Abst 11/326)
6. Berg G, Rothenbacher R, Bode G, Adler G, Brenner H. History of breastfeeding and Helicobacter pylori infection among pre-school children in Germany. Gut 1998;43(Suppl 2):A73 (Abst 09/252)
7. Bode G, Rothenbacher R, Brenner H, Adler G. Prevalence of recurrent abdominal pain in 1,143 pre-school children: Results from a population based study do not confirm a major role of Helicobacter pylori. Gut 1998;43(Suppl 2):A73. (Abst 09/251)
8. Valdambrini V, Lizzoli F, Gissi A, et al. An epidemiological survey on dyspepsia in the age of acquisition of H pylori infection. Gut 1998;43(Suppl 2):A75 (Abst 09/260)
9. Malaty HM. High incidence of Helicobacter pylori infection among children attending day care centers in the United States. Gut 1998;43(Suppl 2):A46 (Abst 05/154)
10. Friedman CR, Glynn MK, Quick R, et al. Helicobacter pylori sero-incidence in a cohort of rural Bolivian children. Gut 1998;43(Suppl 2):A41 (Abst 05/134)
11. Pérez-Pérez GI, Sack RB, Reid R, Santosham M, Blaser MJ. Transient and persistent colonization by Helicobacter pylori in Native American children. Gut 1998;43(Suppl 2):A41. (Abst 05/133)
12. Gasbarrini G, Gasbarrini A, Anti M, et al. The CUE (Catholic University Epidemiological) Study: Prevalence of H pylori infection in a population working at University Hospital. Gut 1998;43(Suppl 2):A43. (05/144)
13. Brenner H, Rothenbacher D, Bode G, Gommel R, Berg G, Adler G. Parental smoking and infection with Helicobacter pylori among pre-school children in Southern Germany. Gut 1998;43(Suppl 2):A45. (Abst 05/151)
14. Dr Mario F, Molaro M, Dal Bò N, et al. Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? Gut 1998;43(Suppl 2):A43. (Abst 05/142)
15. Moran AP, Wadstrom T. Pathogenesis of Helicobacter pylori. Curr Opin Gastroenterol 1998;14:S9-14.
16. Fallone CA, Beech R, Barkun A, Göttke M, Loo V, Nguyen T. The Helicobacter pylori vacA S1 genotype and the cagE gene are associated with gastroduodenal disease. Gut 1998;43(Suppl 2):A19. (Abst 02/55)
17. Menegatti M, Palli D, Miglioli M, Saieva C, Masala G, Vaira D. Cross-sectional study of Helicobocter pylori (Hp) CagA seroprevalence in 1542 patients at first endoscopy through Italy. Gut 1998;43(Suppl 2):A42. (Abst 15/137)
18. Marlicz K, Starzynska T, Jaroszewicz H, et al. CagA, TNF-α and IL-8 seropositivity in gastric carcinoma and accompanying gastric acid secretion and plasma gastrin levels. Gut 1998;43(Suppl 2):A67. (Abst 08/228)
19. Queiroz DMM, Mendes EN, Rocha GA, et al. CagA positive Helicobacter pylori (HP) and risk for developing gastric carcinoma (GC) in Brazil. Gut 1998;43(Suppl 2):A68. (Abst 08/231)
20. Miehlke S, Hackelsberger A, Kirsch C, et al. The Helicobacter pylori vacA s1/m1 genotype is associated with gastric cancer in Germany. Gut 1998;43(Suppl 2):A64. (Abst 08/217)
21. Yamoka Y, Kodama T, Graham DY, Kita M, Imanishi J, Kashima K. No association between the presence of cagA, vacA genotype, age, or clinical outcome: Gastritis, ulcer, or cancer. Gut 1998;43(Suppl 2):A20. (Abst 02/61)
22. Shimoyama T, Fukuda S, Yoshimura T, Neelam B, Munakata A. VacA seropositivity is not associated with the development of gastric cancer in a Japanese population. Gut 1998;43(Suppl 2):A65 (Abst 08/221)
23. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K. Relation between antibody against CagA and VacA and risk for gastric cancer. Gut 1998;43(Suppl 2):A66. (Abst 08/222)
24. Janulaityte D, Kupcinskas L, Pavilonis A, Wadstrom T, Andersen L. Western blot analysis of Helicobacter pylori infection in patients with and without gastric cancer. Gut 1998;43(Suppl 2):A69. (Abst 08/236)
25. Slater ER, Owen RJ. Lack of associations between Helicobacter pylori iceA and vacA genotypes and peptic ulcers in UK patients. Gut 1998;43(Suppl 2):A21. (Abst 02/65)
26. Domingo D, Alarcón T, Sánchez I, Prieto N, Sanz C, López-Brea M. Are cagA, vacA and iceA good markers to determine a Spanish H. pylori strain such as gastritis or ulcer producer? Gut 1998;43(Suppl 2):A23 (Abst 02/74)
27. Oliva G, Romero I, Ayala G, Celis H. Characterization of the inorganic pyrophosphatase of Helicobacter pylori. Gut 1998;43(Suppl 2):A10 (Abst 01/23)
28. Occhialini A, Urdaci M, Sierra R, Munoz N, Covacci A, Mégraud F. Distribution of cag pathogenicity island in Helicobacter pylori gastric cancer isolates. Gut 1998;43(Suppl 2):A21. (Abst 02/66)
29. Negraszus N, Yamaoka Y, Osata M, et al. Geographic distribution of genotypes of the H. pylori vacA gene from gastric cancer and duodenal ulcer isolates. Gut 1998;43(Suppl 2):A22. (Abst 02/68)
30. Go MF, Cissell L, Li L, Graham DY. Are H. Pylori different in gastric ulcers compared to duodenal ulcers? Gut 1998;43(Suppl 2):A22. (Abst 02/69)
31. Neelam B, Forman D, Webb P, Crabtree JE. World wide variation in VacA seropositivity and its association with pepsinogen A:C ratio in Helicobacter pylori positive subjects. Gut 1998;43(Suppl 2):A40. (Abst 05/131)
32. van der Ende A, Pan Z-J, Bart A, et al. CagA-positive H. pylori populations circulating in China and The Netherlands are distinct. Gut 1998;43(Suppl 2):A43. (Abst 05/141)
33. Konturek PC, Steininger H, Taut A, et al. H. pylori (HP) induces apoptosis through activation of Bax and downreguation of bcl-2. Gut 1998;43(Suppl 2):A27. (Abst 03/82)
34. Shimada M, Ina K, Ando T, Sakai T, Kusugami K. Is gastric ulceration associated with epithelial apoptosis mediated by Fas/Fas ligand system? Gut 1998;43(Suppl 2):A19. (Abst 02/56)
35. + H. pylori (HP) strain delays gastric ulcer healing in mouse through induction of apoptosis. Gut 1998;43(Suppl 2):A25 (Abst 03/76)
36. Rokkas T, Ladas S, Liatsos C, et al. Relationship of Helicobacter pylori CagA status to gastric cell proliferation in apoptosis. Gut 1998;43(Suppl 2):A17 (Abst 02/48)
37. Braunschweig I, Nilius M, Peitz U, Malfertheiner P. Inhibits secretory leukocyte protease inhibitor-Mma (Slpi) in gastric epithelial cells Helicobacter pylon infection? Gut 1998;43(Suppl 2):A29. (Abst 03/94)
38. Hida N, Neville P, Dixon MF, Axon ATR, Shimoyama T. Increased mucosal IL-12 (p40) mRNA expression in Helicobacter pylori infected patients with duodenal ulcer. Gut 1998;43(Suppl 2):A27. (Abst 03/86)
39. Sommer F, Faller G, Konturek P, et al. Mucosa infiltrating lymphocytes in Helicobacter pylori gastritis are of a Th1 phenotype. Gut 1998;43(Suppl 2):A34. (Abst 03/115)
40. Shiotani A, Yanaoka K, Iguchi M, et al. Helicobacter pylori infection decreases nitric oxide in the stomach. Gut 1998;43(Suppl 2):A23 (Abst 02/73)
41. D'Elios MM, Manghetti M, Amedei A, et al. Impaired T-cell cytotoxicity in H. pylori-related gastric low grade MALTOma. Gut 1998;43(Suppl 2):A26 (Abst 03/78)
42. Broutet N. Is antral atrophy without intestinal metaplasia really atrophy? Gut 1998;43(Suppl 2):A59. (Abst 07/200)
43. El-Zimaity HMT, Graham DY. Diagnosis of gastric antral atrophy in the presence of H. pylori inflammation and the absence of intestinal metaplasia. Gut 1998;43(Suppl 2):A61. (Abst 07/207)
44. Rácz I, Szabó A, Pécsi Gy, Csöndes M, Erényi Á, Goda M. Gastric metaplasia, acid secretion and duodenal Helicobacter pylori colonization in duodenal ulcer patients. Gut 1998;43(Suppl 2):A61. (Abst 07/210)
45. Yamamoto S, Kaneko H, Hayakawa T, et al. Effect of Helicobacter pylori (HP) eradication on gastric somatostatin (SS) and interleukin-8 (IL-8) levels in peptic ulcer disease: Immunoendocrine interactions. Gut 1998;43(Suppl 2):A18 (Abst 02/53)
46. Annibale B, Marignani M, Ferraro G, et al. Recovery of antral D cells density after eradication of H. pylori infection in patients with atrophic body gastritis (ABG) is associated with a decrease of fasting hypergastrinemia. Gut 1998;43(Suppl 2):A60. (Abst 07/204)
47. Sjöstedt S, Befrits R, Lindberg G, Odman B, Hedenborg L. Two-year histological follow-up after H. pylori eradication in duodenal ulcer patients. Gut 1998;43(Suppl 2):A100. (Abst 11/341)
48. Satoh K, Kihira K, Kimura K. Development of intestinal metaplasia after Helicobacter pylori eradication. Gut 1998;43(Suppl 2):A101. (Abst 11/348)
49. Faller G, Claeys D, Appelmelk B, Negrini R, Kirchner Th. The H,K-ATPase represents an autoimmune target in chronic H. pylori gastritis with body mucosa atrophy. Gut 1998;43(Suppl 2):A27. (Abst 03/85)
50. Huang J-Q, Sridhar S, Chan Y, Hunr RH. Meta-analysis of the relationship of Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
51. Hansen S, Vollset SE, Melby K, et al. Gastric mucosal atrophy is a strong predictory of non-cardia gastric cancer but not of cardia cancer. Gut 1998;43(Suppl 2):A63. (Abst 08/211)
52. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K. Cytokines in gastric mucosa and in gastric cancer associated with H. pylori infection. Gut 1998;43(Suppl 2):A67. (Abst 08/230)
53. Rocco A, Staibano S, Balzano T, et al. Relationship between genomic instability markers and Helicobacter pylori infection in gastric carcinogenesis. Gut 1998;43(Suppl 2):A67. (Abst 08/226)
54. Lee A, Correa P, Roa J, Leung V, O'Rourke J, Dixon MF. The first evidence of dysplasia and possibly gastric cancer caused by natural Helicobacter infection in an animal model. Gut 1998;43(Suppl 2):A66. (Abst 08/223)
55. Simán JH, Forsgren A, Berglund G, Florén C-H. Tobacco smoking and Helicobacter pylori infection are risk factors of gastric adenocarcinoma. Gut 1998;43(Suppl 2):A63 (Abst 08/212)
56. Iaquinto G, Giardullo N, Pasquale L, et al. 54 kDa protein, but not 116 kDa protein, may be considered a serological marker of Helicobacter pylori positive gastric carcinoma. Gut 1998;43(Suppl 2):A70. (Abst 08/240)
57. E-Zimaity HMT, Malaty HM, Gutierrez O, Graham DY. Need for biopsies targeted to the cardia, antrum, and corpus: Gastric MALT lymphoma is a multifocal disease. Gut 1998;43(Suppl 2):A65. (Abst 08/218)
58. Morgner A, Bayerdörffer E, Neubauer A, et al. Cure of Helicobacter pylori infection in 125 patients with primary gastric low-grade MALT lymphoma. Gut 1998;43(Suppl 2):A64. (Abst 08/214)
59. Savio A, Zamboni O, Mombello A, et al. Early stage low grade gastric MALT lymphoma: Long-term post-treatment follow-up after eradication of Helicobacter pylori in a multicentric trial in the North-Eastern Italy. Out 1998;43(Suppl 2):A68. (Abst 08/232)
60. Caroli A, Follador R, Sperti C, et al. Long term follow-up after eradication of Helicobacter pylori in gastric MALT-lymphoma. Gut 1998;43(Suppl 2):A69. (Abst 08/237)
61. Talley NJ, Meineche-Schmidt V, Paré P, et al. Is acid suppression efficacious in non-ulcer dyspepsia? A doubleblind, randomised, controlled trial with omeprazole. Gut 1998;43(Suppl 2):A111. (Abst 13/375)
62. Hengels KJ. Therapeutic efficacy of 15 mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): A multicentre, randomised, double-blind study. Gut 1998;43(Suppl 2):A89. (Abst 10/308)
63. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-7.
64. El-Omar EM, Banerjee S, Wirz A, McColl KE. The Glasgow Dyspepsia Severity Score - a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol 1996;8:967-71.
65. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
66. Talley NJ, Janssens J, Lauritsen K, et al. H. pylori eradication therapy for non-ulcer dyspepsia. A randomized double-blind placebo-controlled long-term trial. Gut 1998;43(Suppl 2):A79. (Abst 10/268)
67. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1875-81.
68. McColl KE, El Nujumi A, Murray L, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997;40:302-6.
69. Jovanovic I, Milosavljevic T, Krstic M, Popovic D, Micev M, Bulajic M. Clinical effect of eradication of Helicobacter pylori in different dyspepsia subgroups. Gut 1998;43(Suppl 2):A92. (Abst 10/320)
70. Dr Mario F, Dal Bò N, Salandin S, et al. Helicobacter pylori (Hp) eradication in functional dyspepsia: A prospective randomized 3 years study. Gut 1998;43(Suppl 2):A80. (Abst 10/272)
71. Passos MCF, Coelho LGV, Gloria ALF, et al. H. pylori eradication for functional dyspepsia : A long-term, randomized, prospective, double-blind, placebo-controlled study. Gut 1998;43(Suppl 2):A81. (Abst 10/276)
72. Koskenpato J, Färkkilä. Quality of life in patients with H. pylori positive functional dyspepsia - A one year follow up study after placebo controlled eradication therapy. Gut 1998;43(Suppl 2):A110. (Abst 13/371)
73. Whelan H, O'Morain M, McNamara D, O'Morain C. Open access C UBT reduces demand on gastroscopy. Gut 1998;43(Suppl 2):A55. (Abst 06/187)
74. Moayyedi P, Mason J, Zilles A, Axon ATR, Chalmers DM, Drummond MF. Screening and treating for H. pylori - Is it cost-effective in clinical practice? Gut 1998;43(Suppl 2):A114. (Abst 13/387)
75. Heaney A, Collins JSA, Watson RGP, McFarland RJ, Bamford KB, Tham TCK. One year follow-up of H. pylori negative dyspeptics - Can gastroscopies be saved in clinical practice? Gut 1998;43(Suppl 2):A114. (Abst 13/388)
76. Vaira D, Malfertheiner P, Megraud F, et al. A novel antigen assay based on stool specimen for Helicobacter pylori (HP): European multicentre study. Gut 1998;43(Suppl 2):A47. (Abst 06/156)
77. Makristathis A, Pasching E, Schütze K, Wimmer M, Rotter ML, Hirschl AM. Detection of Helicobacter pylori in stool specimens by PCR and antigen EIA. Gut 1998;43(Suppl 2):A47. (Abst 06/157)
78. Trevisani L, Sartori S, Galvani F, et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in faeces. Gut 1998;43(Suppl 2):A48. (Abst 06/158)
79. van't Hoff BWM, van der Ende A, van der Hulst RWN, et al. Helicobacter pylori antigen in stool specimen as a possible monitoring tool for eradication therapy. Gut 1998;43(Suppl 2):A49. (Abst 06/163)
80. Veldhuyzen van Zanten S, Bleau BL, Best L, Hutchison D, Blevins J, Thee D. Use of the Helicobacter pylon stool antigen test (HPSAT) for detection of H. pylori (Hp) infection. Gut 1998;43(Suppl 2):A49. (Abst 06/164)
81. Bleau BL, Veldhuyzen van Zanten S, Best L, Hutchison D, Blevins J, Thee D. Determiniation of eradication of Helicobacter pylori (Hp) by the HP stool antigen test (HPSAT). Gut 1998;43(Suppl 2):A50. (Abst 06/166)
82. Gisbert JP, Boixeda D, Bermejo F, et al. Are antral biopsies enough for the diagnosis of Helicobacter pylori eradication with the new one-week triple therapies? Gut 1998;43(Suppl 2):A48. (Abst 06/160)
83. Graham DY, Runke-Garcia D, Anderson S-Y, et al. Comparison of citric acid, sodium citrate, ascorbic acid, glucose, and pentagastrin on urease activity in the UBT. Gut 1998;43(Suppl 2):A51. (Abst 06/170)
84. Martínez MJ, Sanz JC, Alarcón T, García Novo D, López-Brea M. Comparison of citric acid versus polymeric diet for urea breath test results among H. pylori infected children. Gut 1998;43(Suppl 2):A77. (Abst 09/267)
85. Vâzquez Carrasco MA, Jiménez Alonso I, Gisbert Cantó JL, et al. Is fasting required to perform 13C-urea breath test in the diagnosis of H. pylori infection? Gut 1998;43(Suppl 2):A54. (Abst 06/182)
86. 13C urea breath test for the detection of Helicobacter pylori. Gut 1998;43(Suppl 2):A57. (Abst 06/194)
87. 13C-urea breath test (UBT). Gut 1998;43(Suppl 2):A51. (Abst 06/172)
88. 13C-urea breath test in Helicobacter pylori infected subjects. Gut 1998;43(Suppl 2):A53. (Abst 06/180)
89. Neri M. Coccoid forms of H. pylori are a cause of falsely negative urease-based tests. Gut 1998;43(Suppl 2):A48. (Abst 06/161)
90. Bielánski W, Dobrzanska M, Jakuszewska B, et al. Ethanol suppresses H. pylori urease activity as measured by C-urea breath test (UBT). Gut 1998;43(Suppl 2):A57. (Abst 06/195)
91. Sheu BS, Lee SC, Lin PW, Chang YC, Yang SB, Lin XZ. Diagnostic efficacy of carbon 13 urea breath test to detect H. pylori in patients after gastrectomy. Gut 1998;43(Suppl 2):A57. (Abst 06/196)
92. 13C-urea breath test (UBT). Gut 1998;43(Suppl 2):A50. (Abst 06/167)
93. 14C urea breath test (UBT) for Helicobacter pylori (HP) detection. Gut 1998;43(Suppl 2):A56. (Abst 06/189)
94. Malaty HM, Graham DY. Evaluation of Flexsure® HP whole blood in a population of asymptomatic children in day care centers. Gut 1998;43(Suppl 2):A57. (Abst 06/193)
95. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infections. The Mäastrict Consensus Report. Gut 1997;41:8-13.
96. Hunt RH, Thomson, ABR, Consensus Conference participants. First Canadian H pylori Consensus Conference. Can J Gastroenterol 1998;12:31-41.
97. Laine L, Estrada R, Trujillo M, et al. Once-daily therapy for H. pylori: A randomized comparison of four regimens. Gut 1998;43(Suppl 2):A85. (Abst 10/290)
98. Laine L, Suchower L, Connors A, Frantz J, Neil G. Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. trials. Gut 1998;43(Suppl 2):A82. (Abst 10/279)
99. Lamouliatte H, Forestier S, Perie F. Lansoprazole (Lanso) 30 mg or 60 mg combined with two antibiotics [amoxicillin (amox) and clarithromycin (clari)] to eradicate Helicobacter pylori (H. pylori). Gut 1998;43(Suppl 2):A80. (Abst 10/275)
100. Pilotto A, Dal Bò N, Franceschi M, et al. Comparison of three proton pump inhibitors (PPI) in combination with amoxicillin and metronidazole for one week to cure Helicobacter pylori infection in the elderly. Gut 1998;43(Suppl 2):A91. (Abst 10/313)
101. Skálov́ P, Marečková O, Skála I, Lácha J, Teplan V, Vítko Š. Eradication of Helicobacter pylori with clarithromycin: Danger of toxic levels of cyclosporine A. Gut 1998;43(Suppl 2):A109. (Abst 13/370)
102. Sung JY, Chan FKL, Leung WK, et al. One-week therapy of ranitidine bismuth citrate (RBC) with different combinations of antimicrobial for H. pylori infection: Which is the best regimen? Gut 1998;43(Suppl 2):A81. (Abst 10/278)
103. Cestari R, Cort G, Formenti A, et al. Ranitidine bismuth citrate (RBC) based triple therpay for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with H. pylori infection. Gut 1998;43(Suppl 2):A83. (Abst 10/286)
104. Ravizza M, Suriani R, Puglisi F, et al. Helicobacter pylon eradication : RBC plus different antibiotic regimens evaluation in short term therapy. Gut 1998;43(Suppl 2):A85. (Abst 10/292)
105. Susi D. The best treatment for Helicobacter pylori infection among four different 7-day triple therapies. Gut 1998;43(Suppl 2):A80. (Abst 10/273)
106. Aydin A, GÜnsar F, Yilmaz M, et al. Omeprazole, lansoprazole or ranitidine bismuth citrate in combination with amoxicillin plus clarithromycin in Helicobacter pylori eradication. Gut 1998;43(Suppl 2):A89. (Abst 10/307)
107. vd Wouden EJ, Thijs JC, van Zwet AA, Kooy A, Kleibeuker JH. The influence of metronidazole (met) resistance on the efficacy of two triple therapy regimens with ranitidine bismuth citrare (RBC) for H. pylori (HP) infection. Gut 1998;43(Suppl 2):A86. (Abst 10/296)
108. Katicic M, Presecki V, Prskalo M, et al. A new dual and triple therapies in eradicating Helicobacter pylori in peptic ulcer patients. Gut 1998;43(Suppl 2):A87. (Abst 10/298)
109. Okada M, Kawashima M, Nishimura H, et al. Prevalence of H. pylori resistant to antibiotics and a new quadruple therapy. Gut 1998;43(Suppl 2):A83. (Abst 10/285)
110. Comet R, Titó LI, Calvet X, Campo R, García N. Twice a day, four-day, quadruple therapy for treatment of Helicobacter pylori infection: A pilot study. Gut 1998;43(Suppl 2):A90. (Abst 10/312)
111. Glupczynski Y, Burette A, Lamy V, Garrino MG. Evolution of H. pylori primary resistance to antimicrobial agents in Belgium between 1995 and 1998. Gut 1998;43(Suppl 2):A48. (Abst 06/159)
112. van Zwet AA, Kusters JG, Thijs JC, et al. Stable amoxicillin resistance in H. pylori: Isolate from a patient repeatedly treated with antibiotics. Gut 1998;43(Suppl 2):A6. (Abst 01/7)
113. Dore MP, Graham DY, Sepulveda AR. A novel penicillin-binding protein (PBP-D) is involved in amoxicillin resistance in Helicobacter pylori. Gut 1998;43(SuPPl 2):A7. (Abst 01/12)
114. Broutet N, Marais A, Liu D, et al. CAG negative status: A risk factor for failure of Helicobacter pylori triple therapies in non-ulcer dyspepsia. Gut 1998;43(Suppl 2):A79. (Abst 10/270)
115. Gisbert JP, Boixeda D, Bermejo F, et al. Previoius therapy with omeprazole: Does it reduce H. pylori eradication efficacy with the new triple therapies? Gut 1998;43(Suppl 2):A88. (Abst 10/303)
116. Malfertheiner P, Arnim UV, Leodolter A, et al. High compliance in dual & triple therapy, assessed by electronic monitoring in primary care. Gut 1998;43(Suppl 2):A90. (Abst (10/310)
117. Houben MHMG, Schraffordt Koops HS, Rauws EAJ, et al. Efficacy of PPI-triple therapy in H. pylori (Hp) positive patients with ulcer disease versus patients with non-ulcer dyspepsia. Gut 1998;43(Suppl 2):A85. (Abst 10/293)
118. Zullo A, Rinaldi V, Hassan C, et al. Different Helicobacter pylori eradication rates between non-ulcer dyspepsia and peptic ulcer patients. Gut 1998;43(Suppl 2):A92. (Abst 10/319)
119. Veldhuyzen van Zanten S, Leung V, O'Rourke J, Lee A. The gastric transitional zones (TZ) are the areas where Helicobacter treatment fails. Results of a treatment trial using the Sydney strain. Gut 1998;43(Suppl 2):A80. (Abst 10/274)
120. Debets-Ossenkopp YJ, Goodwin A, Vandenbroucke-Grauls CMJE, et al. IS605 insertion in the nitroreductase (rdxA) gene is responsible for metronidazole resistance in H. pylori NCTC 11638. Gut 1998;43(Suppl 2):A5. (Abst 01/2)
121. Kwon DH, Graham DY, El-Zaatari FAK. Transcriptional repression of multiple genes involved in Helicobacter pylori metronidazole resistance. Gut 1998;43(Suppl 2):A6. (Abst 01/5)
122. Heep M, Reischl U, Lehn N. Therapy failure and induction of metronidazole resistance. Gut 1998;43(Suppl 2):A95. (Abst 11/322)
123. Alarcón T, Domingo D, Preito N, López-Brea M. Polymerase chain reaction using 3′ mismatched primers to detected mutation to clarithromycin in Helicobacter pylori clinical isolates. Gut 1998;43(Suppl 2):A10. (Abst 01/21)
124. Peitz U, Sulliga M, Nusch A, et al. Randomised study on the impact of resistance on second-line treatment after failed metronidazoleclarithromycin containing triple therapy. Gut 1998;43(Suppl 2):A83. (Abst 10/282)
125. Best LM, Burford N, Veldhuyzen van Zanten SJO. Helicobacter pylori: Rapid susceptibility testing by flow cytometry. Gut 1998;43(Suppl 2):A9. (Abst 01/18)
126. Broutet N, Guillon F, Sauty E, Lethuaire D, Mégraud F. Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France - Preliminary results. Gut 1998;43(Suppl 2):A11. (Abst 01/28)
127. Glupczynski Y, Andersen LP, López-Brea M, Mégraud F. Toward standardisation of antimicrobial susceptibility testing of H. pylori: Preliminary results by a European multicentre study group. Gut 1998;43(Suppl 2):A47. (Abst 06/155)
128. Chan FKL, Yung MY, Ling TKW, Leung WK, Chung SCS, Jung JY. What is the true impact of metronidazole resistance on the efficacy of bismuth-triple therapy? Gut 1998;43(Suppl 2):A84. (Abst 10/289)
129. Treiber G, Wittig J, Ammon S, Walker S, Klotz U. New short-term quadruple therapies for eradication of Helicobacter pylori (H. pylori) - MACLOR study. Gut 1998;43(Suppl 2):A82. (Abst 10/281)
130. Borda F, Martinez A, Echarri A, Jiminez J, Rodriguez C, Jara C. Clinical practice results of quadruple treatment in Helicobacter pylori eradication failure with OCA-7. Gut 1998;43(Suppl 2):A81. (Abst 10/277)
131. Huelin Benítez J, Jiménez Pérez M, Durán Campos A, et al. Quadruple therapy with omeprazole, tetracycline, metronidazole, and bismuth as a second option after failure of a first eradication therapy. Gut 1998;43(Suppl 2):A86. (Abst 10/295)
132. Perri F, Festa V, Clemente R, et al. Rifabutin in H. pylori eradication after failure of standard triple therapies. Gut 1998;43(Suppl 2):A83. (Abst 10/284)
133. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
134. Queiroz DMM, Oliveira CA, Mendes EN, et al. The risk of Helicobacter pylori infection in the development of gastroesophageal reflux disease. Gut 1998;43(Suppl 2):A110. (Abst 13/372)
135. Wu JCY, Leung WK, Chan FKL, Lai CW, Sung JY. H. pylori infection protects GERD patients against severe esophagitis. Gut 1998;43(Suppl 2):A112. (Abst 13/381)
136. Warburton VJ, McNulty CAM, Shepherd N, et al. The importance of cagA+ Helicobacter pylori to the development of oesophageal disease. Gut 1998;43(Supp 2):A15. (Abst 02/38)
137. McNamara D, Beattie S, Hamilton H, O'Morain C. Sub clinical gastro oesophageal reflux diease in patients with active H. pylori associated duodenal ulcer. Gut 1998;43(Suppl 2):A100. (Abst 11/343)
138. Wurzer H, Schütze K, Kratochvil P, Stupnicki Th. Influence of Helicobacter pylori-infection on healing of gastroesophageal reflux disease (GERD) in patients treated with intravenous pantoprazole. Gut 1998;43(SuPPl 2):A87. (Abst 10/299)
139. Ödman B, Lindberg G, Befrits R, Sjöstedt S. Gastro-oesophageal reflux in duodenal ulcer patients after treatment for H. pylori during a two-year follow-up. Gut 1998;43(Suppl 2):A99. (Abst 11/338)
140. Mantzaris GL, Archavlis Em, Kourtessas D, et al. Oesophagitis does not develop frequently after eradication of Helicobacter pylori infection. Gut 1998;43(Suppl 2):A97. (Abst 11/329)
141. Di Mario F, Dal Bò N, Salandin S, et al. The appearance of GORD in patients with duodenal ulcer after eradication of Helicobacter pylori (Hp) infection: A 4-year prospective study. Gut 1998;43(Suppl 2):A96. (Abst 11/325)
142. Barkun AN, Fallone CA, Mayrand S, Friedman O. Is Helicobacter pylori eradication associated with the endoscopic development of gastro-esophageal disease? Gut 1998;43(Suppl 2):A97. (Abst 11/330)
143. Oünsar F, Aydm A, Ersöz G, et al. An adverse effect of Helicobacter pylori eradication: Gastroesophageal reflux. Gut 1998;43(Suppl 2):A99. (Abst 11/339)
144. Murai T, Miwa H, Nagahara A, Ohkura R, Watanabe S, Sato N. Gastro-esophageal reflux disease (GERD) is developed after cure of Helicobacter pylon infection. Gut 1998;43(Suppl 2):A99. (Abst 11/340)
145. Carbone F, Neri M, Laterza F, et al. Twenty-four hour esophageal pH-metry in patients with non-ulcer dyspepsia is unchanged after H. pylori eradication. Gut 1998;43(Suppl 2):A98. (Abst 11/333)
146. Leodolter A, Domínguez-Muñoz JE, Gerards C, et al. Influence of Helicobacter pylori infection on gastroesophageal reflux pattern in patients with heartburn. Gut 1998;43(Suppl 2):A111. (Abst 13/376)
147. Chan FKL, Sung JY, Suen R, et al. Eradication of H pylori prevents recurrent gastroduodenal hemorrhage in high risk aspirin but not non-aspirin NSAID users. Gut 1998;43(Suppl 2):A79. (Abst 10/269)
148. Konturek JW, Konturek SJ, Stachura J, Domschke W. Helicobacter pylori-positive duodenal ulcer patients do not adapt to aspirin. Gut 1998;43(Suppl 2):A109. (13/367)
149. Avenaud P, Marais A, Monteiro L, Lebail B, Bioulac P, Mégraud F. Detection of Helicobacter sp in the liver of patients with hepatocarcinoma. Gut 1998;43(Suppl 2):A103. (Abst 12/351)
150. Fox JG, Shen Z, Feng F, et al. Enterohepatic Helicobacter spp. identified from humans with primary sclerosing cholangitis. Gut 1998;43(Suppl 2):A115. (Abst 14/391)
151. Carnevale R, Bierti L, Abbiati C, et al. Helicobacter pylori and chronic urticaria: The role of eradication. Gut 1998;43(Suppl 2):A105. (Abst 12/360)
152. Gasbarrini A, Franceschi F, Nucera E, et al. Idiopathic chronic urticaria disappearance after Helicobacter pylori eradication. Gut 1998;43(Suppl 2):A103. (Abst 12/352)
153. Pellicano R, Arena V, Cossotto D, et al. Helicobacter pylori infection and acute myocardial infarction. Gut 1998;43(Suppl 2):A106. (Abst 12/365)
154. Koenig W, Rothenbacher D, Hoffmeister A, et al. Chronic infection with Helicobacter pylori is associated with the risk of coronary heart disease. Results of a case-control study. Gut 1998;43(Suppl 2):A104. (Abst 12/354)
155. Gasbarrini A, Gabrielli M, Fiore G, et al. Helicobacter pylori eradication ameliorates migraine: An extended follow up study. Gut 1998;43(Suppl 2):A105. (Abst 12/358)
156. Franceschi F, Gasbarrini A, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after H. pylori eradication. Gut 1998;43(Suppl 2):A105. (Abst 12/359)
157. Franceschi F, Gasbarrini A, Ricerca BM, et al. High prevalence of H. pylori infection in patients affected by idiopathic sideropenic anemia. Gut 1998;43(Suppl 2):A107. (Abst 12/366)